# Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome

> **NCT05080803** · — · COMPLETED · sponsor: **European School of Advanced Studies in Ophthalmology** · enrollment: 608 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone

## Key facts

- **NCT ID:** NCT05080803
- **Lead sponsor:** European School of Advanced Studies in Ophthalmology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2021-12-23
- **Final completion:** 2022-07-26
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05080803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05080803, "Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05080803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*